{
    "clinical_study": {
        "@rank": "94113", 
        "arm_group": {
            "arm_group_label": "levobupivacaine", 
            "arm_group_type": "Experimental", 
            "description": "group that was administered levobupivacaine plus 60/80/100 mg dextrose"
        }, 
        "brief_summary": {
            "textblock": "Spinal anaesthesia also called spinal block or sub-arachnoid block (SAB), is a form of\n      regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space,\n      generally through a fine needle.\n\n      There is no generic hyperbaric form of levobupivacaine currently available so we aimed in\n      this study that to find the appropriate concentration of the levobupivacaine which achieves\n      unilateral spinal anesthesia. The potential benefits of this type of anesthesia are less\n      motor blockade and urinary retention, decrease in hospital stay. Therefore, it seems to be\n      suitable for outpatient anesthesia."
        }, 
        "brief_title": "Hyperbaric Levobupivacaine for Spinal Anaesthesia", 
        "condition": "This Study Was Focused on Selective Spinal Anesthesia for Lower Extremity Surgery in Order to Achieve Early Mobilization and to Shorten Hospital Stay.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Approval to participate in the study and spinal anesthesia\n\n          -  American society of anesthesia (ASA) I,II physical status\n\n          -  Scheduled for lower extremity surgery\n\n        Exclusion Criteria:\n\n          -  Refuse to participate in the study\n\n          -  American society of anesthesia (ASA)III, IV physical status\n\n          -  Hypersensitivity to local anesthetics\n\n          -  Emergency surgery\n\n          -  Chronic pain treatment\n\n          -  Peripheral neuropathy\n\n          -  Severe systemic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938755", 
            "org_study_id": "odu52"
        }, 
        "intervention": [
            {
                "arm_group_label": "levobupivacaine", 
                "description": "levobupivacaine plus 60 mg dextrose", 
                "intervention_name": "levobupivacaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "levobupivacaine", 
                "description": "levobupivacaine plus 80 mg dextrose", 
                "intervention_name": "levobupivacaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "levobupivacaine", 
                "description": "levobupivacaine plus 100 mg dextrose", 
                "intervention_name": "levobupivacaine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Levobupivacaine", 
                "Bupivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ordu", 
                    "country": "Turkey", 
                    "zip": "52100"
                }, 
                "name": "Anestesia and Reanimation Dept.; Ordu University Education and Research Hospital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Harran University, Medical Faculty, Ethics Committee: TURKEY"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "degree of motor blockade", 
            "safety_issue": "No", 
            "time_frame": "until dissolve of motor blockade"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938755"
        }, 
        "responsible_party": {
            "investigator_affiliation": "T.C. ORDU \u00dcN\u0130VERS\u0130TES\u0130", 
            "investigator_full_name": "\u00f6zg\u00fcr ya\u011fan", 
            "investigator_title": "\u00d6zg\u00fcr Ya\u011fan", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "T.C. ORDU \u00dcN\u0130VERS\u0130TES\u0130", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "T.C. ORDU \u00dcN\u0130VERS\u0130TES\u0130", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}